Figure 4.
AEs of interest during and after the first year of gilteritinib therapy in patients with R/R FLT3+ AML.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.